What is a rare disease therapy worth? David Lapidus discusses this pivotal question for pharmaceutical companies.
At a time of divided politics and diverse opinions, easing the burden of rare diseases is emerging as a cause that everyone can understand and support.
Jean Campbell reflects on why the patient voice needs to be not just heard but acknowledged.
When pharma treats patients as partners, it’s much easier to reach our shared goal of better health. In our final J.P. Morgan blog post, Chris Smith weighs in.
When it comes to orphan drugs, particularly gene therapy, the pricing problem stems from visibility rather than dollars.
At this year’s J.P. Morgan Healthcare Conference, David Lapidus spoke with biopharma investors about our nation’s new leader. Here’s what happened.
Doug Paul provides his perspective on pricing and reimbursement models for gene therapies.
Patti Engel talks about the importance of having experience in the rare disease space.